As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into their automated CGT As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated manufacturing Trenchant BioSystems, tells GEN. CGT-in-a-box. To address those issues, Trenchant is developing a fully-automated cell therapy manufacturing
The new industry deals progressing drug discovery - Drug Discovery Trenchant & Autolomous Partner to Accelerate Cell & Gene Therapy
Private equity investments demand strategic growth, operational excellence, and measurable outcomes. At Trenchant, we specialize in helping businesses achieve Cancer cells video 1
Philip H. Coelho, currently serving as Chairman and CTO of Trenchant BioSystems, Inc. is an engineer/ inventor, educated at the University of California, Davis. Trenchant Bio is making cell and gene therapies (CGT) more affordable and accessible to patients. We were founded in 2022 to create cell therapy manufacturing
Cell and Gene Therapy Manufacturing Challenges & Solutions Fully-Automated CAR-T Bioprocessing Platform Aids Scalability
Trenchant Biosystems As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated CGT manufacturing Under the partnership, the companies will combine fully automated and digitalized technologies aimed at reducing CGT manufacturing timelines
Trenchant, Inc. Trenchant Biosystems specializes in developing scalable and efficient cell therapy manufacturing technologies that streamline processes,
Company — Trenchant Biosystems sunrise video
Philip Coelho - Chairman & CTO of Trenchant BioSystems, Inc Supplier News: Fujifilm Irvine Scientific, Pace Life Sciences
Addressing major obstacles in the development and manufacturing of CGTs with Jon Ellis, CEO of Trenchant BioSystems. Cells video 1 Trenchant BioSystems and Autolomous to Combine Platforms for